Evidence map›Paper›PMID 41332164›Full record

ArticleRenal failure2025

Effect of finerenone on proteinuria reduction in IgA nephropathy.

Guizhen Yu, Meifang Wang, Xue Zhang, Juan Tao, Jie Zhao, Shanshan Liu, Suhan Zhou, Jingyi Zhou, Pingping Ren, Jun Cheng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Guizhen YuKidney Disease Center, the First Affiliated Hospital, College of Medicine, Institute of Nephrology, Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Zhejiang University School of Medicine, Hangzhou, China.
Meifang WangKidney Disease Center, the First Affiliated Hospital, College of Medicine, Institute of Nephrology, Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Zhejiang University School of Medicine, Hangzhou, China.
Xue ZhangKidney Disease Center, the First Affiliated Hospital, College of Medicine, Institute of Nephrology, Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Zhejiang University School of Medicine, Hangzhou, China.
Juan TaoThe First Affiliated Hospital of the USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Jie ZhaoKidney Disease Center, the First Affiliated Hospital, College of Medicine, Institute of Nephrology, Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Zhejiang University School of Medicine, Hangzhou, China.
Shanshan LiuKidney Disease Center, the First Affiliated Hospital, College of Medicine, Institute of Nephrology, Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Zhejiang University School of Medicine, Hangzhou, China.
Suhan ZhouKidney Disease Center, the First Affiliated Hospital, College of Medicine, Institute of Nephrology, Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Zhejiang University School of Medicine, Hangzhou, China.
Jingyi ZhouKidney Disease Center, the First Affiliated Hospital, College of Medicine, Institute of Nephrology, Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Zhejiang University School of Medicine, Hangzhou, China.
Pingping RenKidney Disease Center, the First Affiliated Hospital, College of Medicine, Institute of Nephrology, Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Zhejiang University School of Medicine, Hangzhou, China.
Jun ChengKidney Disease Center, the First Affiliated Hospital, College of Medicine, Institute of Nephrology, Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Zhejiang University School of Medicine, Hangzhou, China.
Jianghua ChenKidney Disease Center, the First Affiliated Hospital, College of Medicine, Institute of Nephrology, Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Zhejiang University School of Medicine, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent studies have suggested a protective effect of finerenone on renal function and reduced the risk of cardiovascular events in patients with CKD and type 2 diabetes. However, its role in IgA nephropathy remains unknown. This study aimed to evaluate its efficacy against IgA nephropathy.

methodsA total of 18 IgAN patients with full supportive therapy, including RAS blockade as much as allowed or tolerated, blood pressure control and steroids and/or other immunosuppressive agents. Analyzed at 2, 4, 6 and 8 months after finerenone therapy.

resultsEighteen IgA nephropathy patients were enrolled in this study, after 6.78 ± 3.47 months follow-up, a significant reduction was observed in protein-to-creatinine ratio with a 28.48% (

conclusionsThe protein-to-creatinine ratio was significantly reduced after finerenone treatment in IgA nephropathy patients with full supportive therapy, and the eGFR was stable during follow-up.

Indexed as

Glomerulonephritis, IGAMineralocorticoid Receptor AntagonistsProteinuriaAdultCreatinineFemaleFollow-Up StudiesGlomerular Filtration RateHumansMaleMiddle AgedNaphthyridinesTreatment OutcomeYoung AdultCreatininefinerenoneMineralocorticoid Receptor AntagonistsNaphthyridinesestimated glomerular filtration ratefinerenoneIgA nephropathyproteinuria

Identifiers

PMID41332164
PMCPMC12677034

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.